Does Cross-neutralization of SARS-CoV-2 Only Relate to High Pathogenic Coronaviruses?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

1. Accounting for Potential Unmeasured Confounding in the Association between Influenza vaccination and COVID-19 Hospitalization: Sensitivity Analysis Using E-value Method.Tanaffos · 2022
   Article
2. Pre-existing humoral immunity to low pathogenic human coronaviruses exhibits limited cross-reactive antibodies response against SARS-CoV-2 in children.Frontiers in immunology · 2022
   Article
3. Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study.Emerging microbes & infections · 2021
   Article
4. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).Viruses · 2021
   Article
5. Antibodies specific to SARS-CoV-2 proteins N, S and E in COVID-19 patients in the normal population and in historical samples.The Journal of general virology · 2021
   Article
6. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.Microbial cell factories · 2021
   Review
7. Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2.Trends in immunology · 2020
   Article
8. HLA, Immune Response, and Susceptibility to COVID-19.Frontiers in immunology
   Review

Corrections and comments

• Commented on by
  Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2.2020
• Comment on
  Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355-359; 2020).2020

Authors and funding

4 authors at 2 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.